

## ESPS Peer-review Report

**Name of Journal:** World Journal of Gastroenterology

**ESPS Manuscript NO:** 6830

**Title:** Novel Therapeutic Targets for Pancreatic Cancer

**Reviewer code:** 00071702

**Science editor:** Cui, Xue-Mei

**Date sent for review:** 2013-10-29 17:38

**Date reviewed:** 2013-11-10 22:31

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> No records	<input checked="" type="checkbox"/> Major revision

## COMMENTS TO AUTHORS

The manuscript looks promising. Collation of information and style of presentation is highly appreciable. The major drawback of the article is lack of thought provoking inputs from the author's end for each segment discussed. In the introduction segment, provide an outline content of the manuscript and also briefly mention regarding the scope of the article. The manuscript does not have a proper concluding segment. The authors must include translational significance for each leads they have discussed at length. In view of above, I recommend a major revision of the manuscript as its not acceptable in its current form.

## ESPS Peer-review Report

**Name of Journal:** World Journal of Gastroenterology

**ESPS Manuscript NO:** 6830

**Title:** Novel Therapeutic Targets for Pancreatic Cancer

**Reviewer code:** 00058434

**Science editor:** Cui, Xue-Mei

**Date sent for review:** 2013-10-29 17:38

**Date reviewed:** 2013-12-14 00:23

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

## COMMENTS TO AUTHORS

Comments to authors: General comments: Authors have collected information from 164 studies to describe novel therapeutic targets for pancreatic cancer, and tried their best to demonstrate each target in detail. Are these targets involved in this manuscript being used in clinical practice? And authors should have an outlook on novel targets of pancreatic cancer at the end of their manuscript. Specific comments: 1. Authors should improve the spelling and disordered grammar expression. For instance, in the first paragraph of introduction, line 5th, “vincinal organs”, and the full name of Rac1 should be “ras-related C3 botulinum toxin substrate 1”. Section 2.2, “Alk4/7, the common receptor for Nodal and Activin, was inhibited by using inhibitor SB431542 and co-administration of gemcitabine can irreversibly deplete CD133 expression which implied that pancreatic cancer stem cell was depleted and the tumorigenicity ability was abrogated when compared to using either treatment alone in in vitro condition [31]” should be rephrased. 2. Please define acronyms when they appear in the manuscript for the first time. 3. Authors should provide more evidence to demonstrate that CTHRC1 can be one of novel targets for pancreatic cancer. And the studies cited in the manuscript should focus on roles of genes in pancreatic cancer. 4. Section 5.3 HER3, authors mentioned that HER3 had no tyrosine kinase property, so how can tyrosine kinase inhibitor (TKIs) inhibit HER3 signaling? Please explain and rephrase.